[
  {
    "ts": null,
    "headline": "Metrorrhagia Market Analysis Report 2025-2035, Profiles of Pfizer, Sandoz, Bayer, Actavis Pharma, Noven Pharmaceuticals, Theramex, Pantarhei Bioscience, AbbVie, Neurocrine Biosciences, Merck",
    "summary": "The global metrorrhagia market is expanding due to an increasing prevalence of gynecological disorders like uterine fibroids and hormonal imbalances, fueling the demand for effective treatments. Despite challenges such as high diagnostic costs and limited awareness, advancements in hormonal and non-hormonal therapies are driving patient adoption. Key developments include targeted drug formulations, innovative surgical techniques, and emerging therapies like selective progesterone receptor modula",
    "url": "https://finnhub.io/api/news?id=912accfef980ebe7e2951d98238df0e4ae3b145a019baac2f55f9a8f0bbfc50f",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1763562720,
      "headline": "Metrorrhagia Market Analysis Report 2025-2035, Profiles of Pfizer, Sandoz, Bayer, Actavis Pharma, Noven Pharmaceuticals, Theramex, Pantarhei Bioscience, AbbVie, Neurocrine Biosciences, Merck",
      "id": 137546410,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "ABBV",
      "source": "Yahoo",
      "summary": "The global metrorrhagia market is expanding due to an increasing prevalence of gynecological disorders like uterine fibroids and hormonal imbalances, fueling the demand for effective treatments. Despite challenges such as high diagnostic costs and limited awareness, advancements in hormonal and non-hormonal therapies are driving patient adoption. Key developments include targeted drug formulations, innovative surgical techniques, and emerging therapies like selective progesterone receptor modula",
      "url": "https://finnhub.io/api/news?id=912accfef980ebe7e2951d98238df0e4ae3b145a019baac2f55f9a8f0bbfc50f"
    }
  },
  {
    "ts": null,
    "headline": "AbbVie Stock Rebounds After Q3 Dip: Time to Buy, Hold or Sell?",
    "summary": "ABBV rebounds after its Q3 dip as strong immunology and neuroscience growth offset Humira erosion and aesthetics weakness.",
    "url": "https://finnhub.io/api/news?id=930613e7be8028dfed893ae65e3fd828783bf46c3808cb88ce2e8451a64999ba",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1763561280,
      "headline": "AbbVie Stock Rebounds After Q3 Dip: Time to Buy, Hold or Sell?",
      "id": 137548645,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "ABBV",
      "source": "Yahoo",
      "summary": "ABBV rebounds after its Q3 dip as strong immunology and neuroscience growth offset Humira erosion and aesthetics weakness.",
      "url": "https://finnhub.io/api/news?id=930613e7be8028dfed893ae65e3fd828783bf46c3808cb88ce2e8451a64999ba"
    }
  },
  {
    "ts": null,
    "headline": "Liver Failure Market Analysis Report 2025-2035: Gilead Sciences, AbbVie, and Boehringer Ingelheim Lead Advancements in Liver Failure Treatments and Artificial Liver Support Technologies",
    "summary": "Liver failure is a critical condition where the liver loses its ability to detoxify, synthesize proteins, and regulate biochemical processes. It can result from hepatitis, alcohol abuse, NAFLD, autoimmune diseases, or toxins. Key symptoms include jaundice, encephalopathy, ascites, and bleeding. The global liver failure market is expanding due to rising disease prevalence, enhanced healthcare access, and diversified therapies. Innovations in transplantation, artificial liver systems, and pharmaco",
    "url": "https://finnhub.io/api/news?id=ff20ecd1aa862ad2bf1c7fcd7d8cc12d741f0941a6a0dbb2807b48097b31d466",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1763560980,
      "headline": "Liver Failure Market Analysis Report 2025-2035: Gilead Sciences, AbbVie, and Boehringer Ingelheim Lead Advancements in Liver Failure Treatments and Artificial Liver Support Technologies",
      "id": 137546411,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "ABBV",
      "source": "Yahoo",
      "summary": "Liver failure is a critical condition where the liver loses its ability to detoxify, synthesize proteins, and regulate biochemical processes. It can result from hepatitis, alcohol abuse, NAFLD, autoimmune diseases, or toxins. Key symptoms include jaundice, encephalopathy, ascites, and bleeding. The global liver failure market is expanding due to rising disease prevalence, enhanced healthcare access, and diversified therapies. Innovations in transplantation, artificial liver systems, and pharmaco",
      "url": "https://finnhub.io/api/news?id=ff20ecd1aa862ad2bf1c7fcd7d8cc12d741f0941a6a0dbb2807b48097b31d466"
    }
  },
  {
    "ts": null,
    "headline": "AbbVie Inc. (ABBV) Is a Trending Stock: Facts to Know Before Betting on It",
    "summary": "AbbVie (ABBV) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.",
    "url": "https://finnhub.io/api/news?id=64c2906ceeb032dc0eb633d75dce5f98cb491032f89f9b47fade0d248b4f8c64",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1763560802,
      "headline": "AbbVie Inc. (ABBV) Is a Trending Stock: Facts to Know Before Betting on It",
      "id": 137548670,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "ABBV",
      "source": "Yahoo",
      "summary": "AbbVie (ABBV) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.",
      "url": "https://finnhub.io/api/news?id=64c2906ceeb032dc0eb633d75dce5f98cb491032f89f9b47fade0d248b4f8c64"
    }
  },
  {
    "ts": null,
    "headline": "3 Cash-Producing Stocks We Think Twice About",
    "summary": "Generating cash is essential for any business, but not all cash-rich companies are great investments. Some produce plenty of cash but fail to allocate it effectively, leading to missed opportunities.",
    "url": "https://finnhub.io/api/news?id=15e9f80537ffff997ab0181150725c2d0d9a4447547f4b7690bbe9005d6d3a40",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1763556041,
      "headline": "3 Cash-Producing Stocks We Think Twice About",
      "id": 137546412,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "ABBV",
      "source": "Yahoo",
      "summary": "Generating cash is essential for any business, but not all cash-rich companies are great investments. Some produce plenty of cash but fail to allocate it effectively, leading to missed opportunities.",
      "url": "https://finnhub.io/api/news?id=15e9f80537ffff997ab0181150725c2d0d9a4447547f4b7690bbe9005d6d3a40"
    }
  },
  {
    "ts": null,
    "headline": "3 Stocks Estimated To Be Trading Below Their Valuations In November 2025",
    "summary": "As the U.S. stock market experiences a period of volatility, with major indices like the S&P 500 and Dow Jones Industrial Average facing consecutive declines, investors are keenly observing the impact of high valuations in sectors such as technology. Amidst these fluctuations, identifying stocks that are potentially trading below their intrinsic value can offer opportunities for those looking to navigate current market conditions wisely.",
    "url": "https://finnhub.io/api/news?id=0ad2a8c9a18740608001f6b83102e61a64e260e7c7bb5c375e262b5a500bd83b",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1763552280,
      "headline": "3 Stocks Estimated To Be Trading Below Their Valuations In November 2025",
      "id": 137546413,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "ABBV",
      "source": "Yahoo",
      "summary": "As the U.S. stock market experiences a period of volatility, with major indices like the S&P 500 and Dow Jones Industrial Average facing consecutive declines, investors are keenly observing the impact of high valuations in sectors such as technology. Amidst these fluctuations, identifying stocks that are potentially trading below their intrinsic value can offer opportunities for those looking to navigate current market conditions wisely.",
      "url": "https://finnhub.io/api/news?id=0ad2a8c9a18740608001f6b83102e61a64e260e7c7bb5c375e262b5a500bd83b"
    }
  },
  {
    "ts": null,
    "headline": "Alkermes escalates bidding war; US biotech risks ‘falling behind’ China",
    "summary": "A bipartisan report warned Congress about China’s growing control over the pharmaceutical supply chain. Elsewhere, Alkermes sweetened its bid for Avadel and Moderna is investing $140 million in U.S. drug production.",
    "url": "https://finnhub.io/api/news?id=30335b03a4fc0a7c4aff8ec0568be693fb2b7bdafc4ac61489c47bfcda5042c2",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1763548380,
      "headline": "Alkermes escalates bidding war; US biotech risks ‘falling behind’ China",
      "id": 137548671,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "ABBV",
      "source": "Yahoo",
      "summary": "A bipartisan report warned Congress about China’s growing control over the pharmaceutical supply chain. Elsewhere, Alkermes sweetened its bid for Avadel and Moderna is investing $140 million in U.S. drug production.",
      "url": "https://finnhub.io/api/news?id=30335b03a4fc0a7c4aff8ec0568be693fb2b7bdafc4ac61489c47bfcda5042c2"
    }
  },
  {
    "ts": null,
    "headline": "Why VYM Is Not A Good Alternative To SCHD",
    "summary": "Discover top US dividend ETFs: Compare VYM vs SCHD for stable yields, growth, and income strategies amid market shifts.",
    "url": "https://finnhub.io/api/news?id=c5563932ada62abe02044bdccad8e3c11fead5a0c21a2908596d047781c4da32",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1763542800,
      "headline": "Why VYM Is Not A Good Alternative To SCHD",
      "id": 137546014,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1990349253/image_1990349253.jpg?io=getty-c-w1536",
      "related": "ABBV",
      "source": "SeekingAlpha",
      "summary": "Discover top US dividend ETFs: Compare VYM vs SCHD for stable yields, growth, and income strategies amid market shifts.",
      "url": "https://finnhub.io/api/news?id=c5563932ada62abe02044bdccad8e3c11fead5a0c21a2908596d047781c4da32"
    }
  }
]